JP2003081807A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003081807A5 JP2003081807A5 JP2001275903A JP2001275903A JP2003081807A5 JP 2003081807 A5 JP2003081807 A5 JP 2003081807A5 JP 2001275903 A JP2001275903 A JP 2001275903A JP 2001275903 A JP2001275903 A JP 2001275903A JP 2003081807 A5 JP2003081807 A5 JP 2003081807A5
- Authority
- JP
- Japan
- Prior art keywords
- calendula
- weight
- melanocytes
- essence
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002752 melanocyte Anatomy 0.000 description 46
- 240000001432 Calendula officinalis Species 0.000 description 39
- 210000001787 dendrite Anatomy 0.000 description 36
- 239000000686 essence Substances 0.000 description 29
- 239000003112 inhibitor Substances 0.000 description 28
- 210000003491 skin Anatomy 0.000 description 24
- 241000208838 Asteraceae Species 0.000 description 23
- 208000003351 Melanosis Diseases 0.000 description 18
- 235000005881 Calendula officinalis Nutrition 0.000 description 17
- 206010014970 Ephelides Diseases 0.000 description 17
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 description 16
- 235000003880 Calendula Nutrition 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 230000005856 abnormality Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 206010061218 Inflammation Diseases 0.000 description 13
- 230000004054 inflammatory process Effects 0.000 description 13
- 210000002540 macrophage Anatomy 0.000 description 13
- 239000000049 pigment Substances 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- -1 acetonitrile Chemical compound 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 10
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 8
- 239000006210 lotion Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000002798 polar solvent Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 208000012641 Pigmentation disease Diseases 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000008099 melanin synthesis Effects 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 3
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical group C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 2
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- PAFJZWHXMSQJKV-UQZRNVAESA-N (3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol;octadecanoic acid Chemical compound OC[C@@H](O)C1OC[C@H](O)[C@H]1O.OC[C@@H](O)C1OC[C@H](O)[C@H]1O.OC[C@@H](O)C1OC[C@H](O)[C@H]1O.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O PAFJZWHXMSQJKV-UQZRNVAESA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 150000005208 1,4-dihydroxybenzenes Chemical class 0.000 description 1
- JPPRXACMNPYJNK-UHFFFAOYSA-N 1-docosoxydocosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCCCCCC JPPRXACMNPYJNK-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- GECRRQVLQHRVNH-MRCUWXFGSA-N 2-octyldodecyl (z)-octadec-9-enoate Chemical compound CCCCCCCCCCC(CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC GECRRQVLQHRVNH-MRCUWXFGSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000002026 carminative effect Effects 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229940082483 carnauba wax Drugs 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 125000005131 dialkylammonium group Chemical group 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 229940114937 microcrystalline wax Drugs 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Description
【特許請求の範囲】
【請求項1】
キク科(Compositae)のキンセンカ属植物(Calendula)のトウキンセンカ(Calendula
officinalis L.)の頭花から極性溶媒により抽出したエッセンスを含む、メラノサイトのデンドライトの伸長抑制剤。
【請求項2】
キク科(Compositae)のキンセンカ属植物(Calendula)のトウキンセンカ(Calendula
officinalis L.)の頭花から極性溶媒により抽出したエッセンスを含む、マクロファージ由来のデンドライト伸長促進因子の抑制剤。
[Claims]
(1)
Deng calendula calendula plant belonging to the genus of the Asteraceae (Compositae) (Calendula) (Calendula
officinalis L.) , a melanocyte dendrite elongation inhibitor containing an essence extracted from a flower head with a polar solvent .
(2)
Calendula of Calendula, a member of the family Asteraceae (Compositae)
officinalis L.), a macrophage-derived dendrite elongation promoting factor inhibitor containing essence extracted with a polar solvent.
【0001】
【発明の属する技術分野】
本発明は、メラノサイトのデンドライトの伸長抑制剤に関する。
[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to Dendorai preparative elongation inhibitor melanocytes.
他方、メラノサイトによって産生されるメラニン顆粒の異常によって生じる色素異常の解決は、美しい白い肌を具現化するための人類永年の解決課題であり、この為、種々の努力が為され、多くの成果が得られてきており、そのメカニズムについても様々なものが得られているが、メラノサイトのデンドライトの伸長抑制に着目したものはなく、この様なメカニズムにより、光の関与する色素異常であって、炎症を伴う色素異常症の予防や改善などの対応にキク科(Compositae)のキンセンカ属植物(Calendula)のトウキンセンカ(Calendula officinalis L.)の頭花から極性溶媒により抽出したエッセンスが有用であることは全く知られていない。又、炎症を伴った色素異常やソバカスなどの色素異常に対
して、従来良く知られているアスコルビン酸などのメラニン生成阻害剤の効果が今ひとつであり、この様な色素異常の予防或いは改善手段の開発が望まれていた。
On the other hand, resolving pigment abnormalities caused by abnormal melanin granules produced by melanocytes is a long-standing problem for humankind to embody beautiful white skin, and for this reason, various efforts have been made and many results have been achieved. Although various mechanisms have been obtained, none of them focused on the suppression of dendritic elongation of melanocytes. Of the essence extracted with a polar solvent from the head flower of Calendula offspring (Calendula officinalis L.) of the Calendula plant of the family Asteraceae (Compositae) for prevention and improvement of pigmentation disorders associated with Not known at all. In addition, the effect of a well-known melanin production inhibitor such as ascorbic acid on pigment abnormalities such as inflammation and pigment abnormalities such as freckles is only one, and there is no means of preventing or improving such pigment abnormalities. Development was desired.
更に、キク科(Compositae)のトウキンセンカ(Calendula officinalis L.)のエキスは、精油、苦味質、樹脂、カレンデュリンと称するゴム質を含み、芳香性苦味薬として用いられ、外傷にも利用される。又、頭花の乾燥したものが駆風、興奮剤として使われ、健胃、駆虫薬などの民間薬にされた。若芽や葉は、食用になり、飼料にも使われた。しかしながら、このエッセンスが、メラノサイトのデンドライトの伸長を抑制する作用を有していることは全く知られておらず、従って、このものを含有する化粧料などの皮膚外用剤がメラノサイトのデンドライトの伸長を抑制し、以て、色素異常、取り分け、光が関与し、炎症を伴って起こる色素異常の予防と改善に有用であることは全く知られていないことであった。
Furthermore, extracts of Calendula officinalis L. of the family Asteraceae (Compositae) include essential oils, bitter substances, resins, and rubber substances called calendulin, are used as aromatic bitter medicines, and are also used for trauma. Dried head flowers were also used as carminative and stimulants, and were used as folk medicine such as stomach and anthelmintic. The young shoots and leaves became edible and used for feed. However, it is not known at all that this essence has an action of suppressing the elongation of melanocyte dendrite, and therefore, a skin external preparation such as a cosmetic containing the same has the effect of suppressing the elongation of melanocyte dendrite . It is known that it is not useful for preventing and improving pigment abnormalities, which are associated with pigment abnormalities, particularly, light, and are accompanied by inflammation.
【0005】
【発明が解決しようとする課題】
本発明は、この様な状況下為されたものであり、炎症を伴った色素異常やソバカスなどの色素異常に対して有効な予防或いは改善手段として好適なメラノサイトのデンドライトの伸長抑制剤を提供することを課題とする。
[0005]
[Problems to be solved by the invention]
The present invention, all SANYO was made under such circumstances, the elongation inhibitors suitable melanocyte dendrites as effective prophylactic or improvement measures against pigmentation disorders, such as abnormal pigmentation and freckles accompanied by inflammation The task is to provide.
【0006】
【課題の解決手段】
この様な状況に鑑みて、本発明者らは、炎症を伴った色素異常やソバカスなどの色素異常に対して有効な予防或いは改善手段を求めて、鋭意研究を重ねた結果、キク科(Compositae)のトウキンセンカ(Calendula officinalis L.)のエッセンスに優れたメラノサイトのデンドライトの伸長抑制作用を見出し、発明を完成させるに至った。即ち、本発明は次に示す技術に関するものである。
(1) キク科(Compositae)のキンセンカ属植物(Calendula)のトウキンセンカ(Calendula officinalis L.)の頭花から極性溶媒により抽出したエッセンスを含む、メラノサイトのデンドライトの伸長抑制剤。
(2)キク科(Compositae)のキンセンカ属植物(Calendula)のトウキンセンカ(Calendula officinalis L.)の頭花から極性溶媒により抽出したエッセンスを含む、マクロファージ由来のデンドライト伸長促進因子の抑制剤。
以下、本発明について、実施の形態を中心に詳細に説明を加える。
[0006]
[Means for solving the problem]
In view of such a situation, the present inventors have intensively studied for effective prevention or improvement measures for pigment abnormality accompanied by inflammation and pigment abnormality such as freckles. tow calendula) (to Heading the extension inhibitory effect of dendrite of excellent melanocytes to Essen vinegar calendula officinalis L.), it has led to the completion of the inventions. That is, the present invention relates to the following technology.
(1) A melanocyte dendrite elongation inhibitor comprising an essence extracted from a flower of a calendula offspring (Calendula officinalis L.) of a calendula plant of the family Asteraceae (Compositae) with a polar solvent .
(2) An inhibitor of a macrophage-derived dendrite elongation promoting factor, comprising an essence extracted from a flower of a calendula offspring (Calendula officinalis L.) of a calendula plant of the family Asteraceae (Compositae) with a polar solvent.
Hereinafter, the present invention will be described in detail focusing on embodiments.
【0007】
【発明の実施の形態】
(1)本発明のメラノサイトのデンドライトの伸長抑制剤
本発明のメラノサイトのデンドライトの伸長抑制剤は、キク科(Compositae)のキンセンカ属植物(Calendula)のトウキンセンカ(Calendula officinalis L.)の頭花から極性溶媒により抽出したエッセンスを含む。ここで、エッセンスとは、かかる植物の頭花の極性有機溶媒による抽出物、抽出物の溶媒を除去した、溶媒除去物、乃至はその溶媒除去物をカラムクロマトグラフィーや液液抽出で精製した精製分画物などの総称を意味する。この様な極性溶媒としては、例えば、水、エタノール、メタノール、1,3−ブタンジオール、プロピレングリコールなどのアルコール類、酢酸エチルや蟻酸メチルなどのエステル類、アセトンやメチルエチルケトンなどのケトン類、クロロホルムや塩化メチレン等のハロゲン化炭化水素類、アセトニトリル等のニトリル類、ジエチルエーテルやテトラヒドロフランなどのエーテル類から選ばれる1種乃至は2種以上が好ましく例示できる。これらの内、特に好ましいものは、水乃至はアルコールである。この様な抽出物を作成するには、植物体乃至はその加工物に1〜10倍量の溶媒を加え、室温であれば数日、沸点付近の温度であれば数時間浸漬すればよい。しかる後に、不溶物を濾過などで除去し、必要に応じて減圧濃縮や凍結乾燥により溶媒除去することが出来る。キク科(Compositae)のトウキンセンカ(Calendula officinalis L.)の頭花の場合、各部分を50%エタノール抽出後、濾過し、減圧濃縮する、そして場合によって凍結乾燥するのがエッセンスとして特に好ましい。それは、頭花の部分がメラノサイトのデンドライドの伸長抑制成分が多く含まれており、特に好ましいからである。かくして得られた、本発明のメラノサイトのデンドライトの伸長抑制剤である、キク科(Compositae)のトウキンセンカ(Calendula officinalis L.)の頭花のエッセンスは、メラノサイトがデンドライトを伸長するのを抑制する作用に優れ、以て、メラノサイトより皮膚組織へメラニン顆粒が移動するのを抑制し、この様なメラニン顆粒の移動をメカニズムとする、光照射時に生じる、炎症を伴った黒化やソバカスなどの色素異常を予防或いは改善する作用を有する。この様な作用は、マクロファージが放出するメラノサイトのデンドライトの伸長因子がメラノサイトに働きかけるのを阻害することを機序としていると考えられる。勿論、色素異常が、メラニン顆粒の産生にあたってこの様なルートをとることから、本発明のメラノサイトのデンドライト伸長抑制剤は、光照射による炎症を伴った黒化やソバカス以外の色素異常も抑制するが、この様な色素異常は他の手段でも予防や改善が可能であるため、本発明の効果の特徴は前記の光照射時に生じる、炎症を伴った黒化やソバカスなどの色素異常を予防或いは改善する作用と言える。又、この様なエッセンスにはチロシナーゼ活性阻害やメラニン産生阻害作用を有する物質も含まれているため、この様な作用を目的として美白用の化粧料に含有させることも出来る。
[0007]
BEST MODE FOR CARRYING OUT THE INVENTION
(1) The melanocyte dendrite elongation inhibitor of the present invention The melanocyte dendrite elongation inhibitor of the present invention is obtained from the head flower of Calendula officinalis L. of a calendula plant of the family Asteraceae (Compositae). containing essences extracted with a polar solvent. In here, the essence, extract according polar organic solvents head flower such plants, solvent extracts was removed, the solvent removed substance, or the purification of the solvent removed substance by column chromatography or liquid-liquid extraction Generic name such as purified fractions. The polar solvent such as this, for example, water, ethanol, methanol, 1,3-butanediol, alcohols such as propylene glycol, esters such as ethyl acetate and methyl formate, ketones such as acetone and methyl ethyl ketone, chloroform Preferred examples include one or more selected from halogenated hydrocarbons such as methane and methylene chloride, nitriles such as acetonitrile, and ethers such as diethyl ether and tetrahydrofuran. Of these, water and alcohol are particularly preferred. In order to prepare such an extract, a 1 to 10-fold amount of a solvent is added to the plant or its processed product, and immersed for several days at room temperature or several hours at a temperature near the boiling point. Thereafter, insolubles are removed by filtration or the like, and if necessary, the solvent can be removed by concentration under reduced pressure or lyophilization. If head flower toe calendula Asteraceae (Compositae) (Calendula officinalis L.) , after the parts 50% ethanol extraction, filtration, vacuum concentrated, and particularly preferred as essence of lyophilized some cases. This is because the head flower portion is particularly preferable because it contains a large amount of a melanocyte dendrite elongation inhibitory component. The essence of the head flower of Calendula officinalis L. of the family Asteraceae (Compositae), which is the melanocyte dendrite elongation inhibitor of the present invention thus obtained, suppresses the melanocyte elongation of dendrite. It inhibits the movement of melanin granules from melanocytes to skin tissue, and the mechanism of such movement of melanin granules causes pigmentation abnormalities such as inflammation-induced blackening and freckles caused by light irradiation. Has the effect of preventing or improving It is considered that such an action has a mechanism of inhibiting the action of a dendritic elongation factor of melanocytes released by macrophages on melanocytes. Of course, since the pigment abnormality takes such a route in the production of melanin granules, the melanocyte dendrite elongation inhibitor of the present invention also suppresses pigmentation abnormalities other than blackening and freckles accompanied by inflammation by light irradiation. Since such pigment abnormalities can be prevented or ameliorated by other means, the feature of the effect of the present invention is to prevent or ameliorate pigment abnormalities such as inflammation-induced blackening and freckles that occur during light irradiation. It can be said that it works. Further, since such an essence contains a substance having an inhibitory action on tyrosinase activity or melanin production, it can be contained in a whitening cosmetic for the purpose of such an action .
(2)本発明のメラノサイトのデンドライトの伸長抑制剤の皮膚外用剤への応用
本発明のメラノサイトのデンドライトの伸長抑制剤は、マクロファージが放出するメラノサイトのデンドライトの伸長因子がメラノサイトに働きかけるのを阻害することを機序
としているので、メラノサイトとマクロファージとが協調的に働く生命現象を抑制することが出来、この様なメラノサイトのデンドライトの伸長抑制剤を、メラノサイトとマクロファージが関与する皮膚現象用の皮膚外用剤として用いると好ましい。ここで、本発明の皮膚外用剤は、メラノサイトとマクロファージが関与する皮膚現象対応用であって、本発明のメラノサイトのデンドライトの伸長抑制剤を含有することを特徴とする。ここで、本発明で言う皮膚外用剤とは、皮膚に外用で適用される組成物の総称であって、貼付剤を含む皮膚外用医薬や洗浄剤を含む化粧料が好ましく例示でき、これらの内では、化粧料であることが特に好ましい。これは、本発明のメラノサイトのデンドライトの伸長抑制剤の安全性が高く、作用が穏やかであるためである。メラノサイトとマクロファージが関与する皮膚現象としては、特に好ましくは前述の光照射による炎症を伴った黒化やソバカスなどの色素異常がまず一番重要な課題として挙げられるが、その他炎症反応なども含まれる。本発明に係るメラノサイトとマクロファージが関与する皮膚現象対応用の皮膚外用剤に於ける、メラノサイトのデンドライトの伸長抑制剤の好ましい含有量は、皮膚外用剤全量に対して、0.001重量%〜10重量%であり、更に好ましくは0.01重量%〜5重量%である。これは、少なすぎるとデンドライトの伸長抑制作用が発揮されない場合があり、多すぎても効果が頭打ちになり他の処方成分の自由度を損なうことがあるからである。
(2) elongation inhibitor dendrites of melanocytes applications present invention to the skin external preparation of the elongation inhibitor melanocyte dendrites of the present invention, elongation factor dendrites of melanocytes macrophages release to inhibit the act on melanocytes because it is a mechanism that, it is possible to suppress the life phenomenon in which the melanocytes and the macrophages work cooperatively, the extension inhibitor of dendrite of such melanocytes, skin for skin phenomenon eyes Ranosaito and macrophages are involved It is preferably used as an external preparation. Here, the external preparation for skin of the present invention is a skin phenomenon corresponding to melanocytes and macrophages are involved, characterized in that it contains a stretch inhibitor dendrites of melanocytes present invention. Here, the external preparation for skin referred to in the present invention is a generic name of a composition applied externally to the skin, and a skin external medicine including a patch and a cosmetic including a cleansing agent can be preferably exemplified. Then, it is particularly preferred that the composition is a cosmetic. This high safety extension inhibitor dendrites of melanocytes present invention, because the action is moderate. As skin phenomena involving melanocytes and macrophages, particularly preferably pigmentation abnormalities such as blackening and freckles accompanied by inflammation by light irradiation are mentioned as the most important issues, but also include other inflammatory reactions . The preferred content of melanocytes and macrophages in the skin external agent for the skin phenomena corresponding involved, melanocyte dendrite elongation inhibitor according to the present invention, relative to the total amount of the skin treatment composition, 0.001% to 10 %, More preferably 0.01% to 5% by weight. This is because if the amount is too small, the effect of suppressing dendrite elongation may not be exhibited, and if the amount is too large, the effect may reach a plateau and the degree of freedom of other formulation components may be impaired.
本発明に係るメラノサイトとマクロファージが関与する皮膚現象対応用の皮膚外用剤は、抗炎症剤として知られる、プレドニゾロン、ヒドロコルチゾン、デキサメタゾン、インドメタシン、ジクロフェナックナトリウム等を配合させれば相乗効果により日光による炎症を伴う黒化症に有意義である。また、上記必須成分以外に、通常化粧料や皮膚外用医薬で使用される任意の成分を含有することが出来る。かかる任意成分としては、例えば、スクワラン、ワセリン、マイクロクリスタリンワックス等の炭化水素類、ホホバ油、カルナウバワックス,オレイン酸オクチルドデシル等のエステル類、オリーブ油、牛脂、椰子油等のトリグリセライド類、ステアリン酸、オレイン酸、リチノレイン酸等の脂肪酸、オレイルアルコール、ステアリルアルコール、オクチルドデカノール等の高級アルコール、スルホコハク酸エステルやポリオキシエチレンアルキル硫酸ナトリウム等のアニオン界面活性剤類、アルキルベタイン塩等の両性界面活性剤類、ジアルキルアンモニウム塩等のカチオン界面活性剤類、ソルビタン脂肪酸エステル、脂肪酸モノグリセライド、これらのポリオキシエチレン付加物、ポリオキシエチレンアルキルエーテル、ポリオキシエチレン脂肪酸エステル等の非イオン界面活性剤類、ポリエチレングリコール、グリセリン、1,3−ブタンジオール等の多価アルコール類、増粘・ゲル化剤、酸化防止剤、紫外線吸収剤、色剤、防腐剤、粉体等を含有することができる。勿論、従来のメラニン産生抑制剤である、アスコルビン酸類やアルブチンなどのハイドロキノン類を含有することも相乗的な効果を発揮する場合があり、有利である。
The topical skin preparation for treating skin phenomena involving the melanocytes and macrophages according to the present invention is known as an anti-inflammatory agent, prednisolone, hydrocortisone, dexamethasone, indomethacin, diclofenac sodium, etc. Significant for accompanying melanosis. Further, in addition to the above essential components, any components usually used in cosmetics or external medicine for skin can be contained. Such optional components include, for example, hydrocarbons such as squalane, petrolatum, and microcrystalline wax, jojoba oil, carnauba wax, esters such as octyldodecyl oleate, triglycerides such as olive oil, tallow, coconut oil, and stearic acid. Oleic acid, fatty acids such as ritinoleic acid, higher alcohols such as oleyl alcohol, stearyl alcohol, and octyl dodecanol; anionic surfactants such as sulfosuccinates and sodium polyoxyethylene alkyl sulfate; and amphoteric surfactants such as alkyl betaine salts. Agents, cationic surfactants such as dialkylammonium salts, sorbitan fatty acid esters, fatty acid monoglycerides, their polyoxyethylene adducts, polyoxyethylene alkyl ethers, polyoxyethylene Nonionic surfactants such as fatty acid esters, polyhydric alcohols such as polyethylene glycol, glycerin and 1,3-butanediol, thickening / gelling agents, antioxidants, ultraviolet absorbers, coloring agents, preservatives , Powder and the like. Of course, the addition of hydroquinones such as ascorbic acids and arbutin, which are conventional melanin production inhibitors, may also exert a synergistic effect, which is advantageous.
<実施例1>
キク科(Compositae)のトウキンセンカ(Calendula officinalis L.)の頭花のエッセンスは、頭花500gに5lの50%エタノールを加え、攪拌しながら一週間、室温で抽
出し、濾過して不溶物を取り除き、更に減圧濃縮をして、その後、凍結乾燥した。そして、本発明のメラノサイトのデンドライトの伸長抑制剤であるスイカズラのエッセンス1を得た。
<Example 1>
The essence of the head flower of Calendula officinalis L. of the family Asteraceae (Compositae) is obtained by adding 5 l of 50% ethanol to 500 g of the head flower, extracting with stirring for one week at room temperature, and filtering to remove insoluble matter. It was removed, further concentrated under reduced pressure, and then freeze-dried. Then, to obtain a honeysuckle essence 1 is elongated inhibitor dendrites of melanocytes present invention.
<実施例2>
キク科(Compositae)のトウキンセンカ(Calendula officinalis L.)の頭花のエッセンスは、頭花500gに5lの50%エタノールを加え、攪拌しながら2時間、90℃で加熱し、室温まで冷却した後、濾過して不溶物を取り除き、更に減圧濃縮をして、その後、凍結乾燥した。そして、本発明のメラノサイトのデンドライトの伸長抑制剤であるトウキンセンカのエッセンス2を得た。
<Example 2>
The essence of the head flower of Calendula officinalis L. of the family Asteraceae (Compositae) is obtained by adding 5 l of 50% ethanol to 500 g of the head flower, heating at 90 ° C. for 2 hours with stirring, and cooling to room temperature. Then, the mixture was filtered to remove insolubles, further concentrated under reduced pressure, and then freeze-dried. Then, to obtain the essence 2 tow calendula is elongated inhibitor dendrites of melanocytes present invention.
<実施例3>
キク科(Compositae)のトウキンセンカ(Calendula officinalis L.)の頭花のエッセンスは、頭花500gに5lの50%メタノールを加え、攪拌しながら2時間、90℃で加熱し、室温まで冷却した後、濾過して不溶物を取り除き、更に減圧濃縮をして、その後、凍結乾燥した。そして、本発明のメラノサイトのデンドライトの伸長抑制剤であるトウキンセンカのエッセンス3を得た。
<Example 3>
The essence of the head flower of Calendula officinalis L. of the family Asteraceae (Compositae) is obtained by adding 5 l of 50% methanol to 500 g of the head flower, heating at 90 ° C. for 2 hours with stirring, and cooling to room temperature. Then, the mixture was filtered to remove insolubles, further concentrated under reduced pressure, and then freeze-dried. Then, to obtain the essence 3 toe calendula is elongated inhibitor dendrites of melanocytes present invention.
<実施例4>
上記実施例1、2、3のメラノサイトのデンドライトの伸長抑制剤を用いて、デンドライト伸長抑制作用を調べた。即ち、予め常法に従い、マウス腹腔より、マクロファージを回収し、10%FBS加イーグルの最少培地で希釈し、2×10 6 セル/mlの濃度のマクロファージ液を調製しておいた。このものを90μlずつ35mmシャーレに分注し、これに0.05mW/cm 2 で20分間の紫外線照射を行った。これらにメラノサイトのデンドライトの伸長抑制剤であるトウキンセンカのエッセンス1、2及び3を乾燥重量%で0.005%となるようDMSOに溶かして加え37℃で1晩培養した。又、他方マウスの尾を切り、尾の表皮を細かく刻みシャーレに入れ0.5%トリプシンにて37℃で一晩処理し、ピンセットを用いて、表皮と真皮に分離し、表皮のみを回収し、0.5%トリプシンにて37℃で20分間処理し、フィルター濾過でメラノサイトのみを濾液として集めた。このメラノサイトを含む濾液を、イーグルの最少培地に10%FBS、10 -4 MのIBMX及び10ng/mlのTPAを加えた培地で、37℃、48時間培養した。これを同培地で懸濁させ、96穴ウェルに1000セル/ウェルずつ分注し、37℃で一晩培
養した。メラノサイトの培地を捨て、PBSで3回洗浄した後、10%FBS加イーグルの最少培地35μlに置換した。これに前記検体を含むマクロファージの培養上清35μlずつ添加し、37℃で二晩培養し、光学顕微鏡下写真撮影を行い、この写真よりデンドライトの長さを測定した。結果を表1に示す。これより、本発明のメラノサイトのデンドライトの伸長抑制剤であるトウキンセンカのエッセンス1、2及び3はデンドライト伸長の抑制作用に優れることが分かる。
(検体)
1)UV照射+メラノサイトのデンドライトの伸長抑制剤であるトウキンセンカのエッセンス1のDMSO溶液(0.005%)
2)UV照射+メラノサイトのデンドライトの伸長抑制剤であるトウキンセンカのエッセンス2のDMSO溶液(0.005%)
3)UV照射+メラノサイトのデンドライトの伸長抑制剤であるトウキンセンカのエッセンス3のDMSO溶液(0.005%)
4)UV照射のみ(ポジティブコントロール)
5)UV非照射のみ(ネガティブコントロール)
<Example 4>
With elongation inhibitor dendrites of melanocytes of Example 1, 2 and 3 were examined dendrite outgrowth inhibition action. That is, macrophages were collected from the mouse abdominal cavity in advance and diluted with a minimal medium containing 10% FBS-added Eagle according to a conventional method to prepare a macrophage solution having a concentration of 2 × 10 6 cells / ml. This was dispensed in 90 μl portions into a 35 mm petri dish, and this was irradiated with ultraviolet light at 0.05 mW / cm 2 for 20 minutes. Essences 1, 2, and 3 of Calendula officinalis, which are inhibitors of elongation of melanocyte dendrite , were dissolved in DMSO to a dry weight percentage of 0.005%, and cultured at 37 ° C. overnight. On the other hand, the tail of the mouse was cut off, the epidermis of the tail was finely chopped, placed in a petri dish, treated with 0.5% trypsin at 37 ° C. overnight, separated into epidermis and dermis using forceps, and only the epidermis was collected. And 0.5% trypsin for 20 minutes at 37 ° C., and only melanocytes were collected as a filtrate by filtration. The filtrate containing the melanocytes was cultured at 37 ° C. for 48 hours in a medium in which 10% FBS, 10 −4 M IBMX and 10 ng / ml TPA were added to Eagle's minimal medium. This was suspended in the same medium, dispensed into a 96-well well at a rate of 1000 cells / well, and cultured at 37 ° C. overnight. The melanocyte medium was discarded, washed three times with PBS, and then replaced with 35 μl of a minimum medium of Eagle supplemented with 10% FBS. To this, 35 μl of the culture supernatant of the macrophage containing the specimen was added, and the mixture was cultured at 37 ° C. for two nights, a photograph was taken under an optical microscope, and the length of the dendrite was measured from this photograph. Table 1 shows the results. From this, essences 1, 2 and 3 of the toe calendula is elongated inhibitor dendrites of melanocytes of the invention it can be seen that excellent inhibition of dendrite elongation.
(Sample)
1) of the tow calendula essence of 1 is elongated inhibitor dendrites of UV radiation + melanocytes DMSO solution (0.005%)
2) UV irradiation + DMSO solution of essence 2 of calendula officinalis, which is an inhibitor of melanocyte dendrite elongation (0.005%)
3) UV irradiation + DMSO solution of Essence 3 of calendula officinalis, which is an inhibitor of melanocyte dendrite elongation (0.005%)
4 ) UV irradiation only (positive control)
5 ) UV non-irradiation only (negative control)
<応用例1>
以下に示す処方で化粧水を作成した。即ち、処方成分を室温で攪拌可溶化して化粧水を得た。この化粧水について、シミ、そばかすに悩むパネラー1群3名を用いて、1ヶ月間、朝晩1日2回使用してもらいそのシミ、そばかすの予防及び改善効果を評価してもらった。評価基準は、評点2:著しい改善、評点1:明らかな改善、評点0.5:わずかな改善、評点0:改善なしの基準である。平均評点は0.91であった。本発明のメラノサイトのデンドライトの伸長抑制効果のあるトウキンセンカのエッセンス1を含有する化粧水は、シミ、そばかすの改善に効果のあることが認められた。
実施例1のトウキンセンカのエッセンス1 1.0 重量部
1,3−ブタンジオール 5.0 重量部
グリセリン 3.0 重量部
クエン酸ナトリウム 0.1 重量部
メチルパラベン 0.2 重量部
エタノール 8 重量部
水 82.7 重量部
< Application Example 1 >
A lotion was prepared according to the following formulation. That is, the ingredients were stirred and solubilized at room temperature to obtain a lotion. This lotion, stain, using the panelists 1 group 3 people suffer from freckles, one month, the stains, were asked to evaluate the effect of preventing and improving freckles asked to use 2 times morning and evening daily. The evaluation criterion is a criterion of rating 2 : marked improvement, rating 1 : obvious improvement, rating 0.5 : slight improvement, rating 0 : no improvement. The average score was 0.91. Lotion containing essence 1 tow calendula with outgrowth inhibition effect of Dendorai bets melanocytes present invention, stain, to be effective in improving freckles were observed.
Calendula essence 1 of Example 1 1 part by weight 1,3-butanediol 5.0 parts by weight Glycerin 3.0 parts by weight Sodium citrate 0.1 parts by weight Methylparaben 0.2 parts by weight Ethanol 8 parts by weight Water 82.7 parts by weight
<応用例2>
以下に示す処方で化粧水を作成した。即ち、処方成分を室温で攪拌可溶化して化粧水を得た。この化粧水について、シミ、そばかすに悩むパネラー1群3名を用いて、1ヶ月間、朝晩1日2回使用してもらいそのシミ、そばかすの予防及び改善効果を評価してもらった。評価基準は、評点2:著しい改善、評点1:明らかな改善、評点0.5:わずかな改善、評点0:改善なしの基準である。平均評点は0.86であった。本発明のメラノサイ
トのデンドライドの伸長抑制効果のあるトウキンセンカのエッセンス2を含有する化粧水は、シミ、そばかすの改善に効果のあることが認められた。
実施例2のトウキンセンカのエッセンス2 1 重量部
1,3−ブタンジオール 5 重量部
グリセリン 3 重量部
クエン酸ナトリウム 0.1 重量部
メチルパラベン 0.2 重量部
エタノール 8 重量部
水 82.7 重量部
< Application Example 2 >
A lotion was prepared according to the following formulation. That is, the ingredients were stirred and solubilized at room temperature to obtain a lotion. This lotion, stain, using the panelists 1 group 3 people suffer from freckles, one month, the stains, were asked to evaluate the effect of preventing and improving freckles asked to use 2 times morning and evening daily. The evaluation criterion is a criterion of rating 2 : marked improvement, rating 1 : obvious improvement, rating 0.5 : slight improvement, rating 0 : no improvement. The average score was 0.86. It was confirmed that the lotion containing the essence 2 of Calendula officinalis having the effect of suppressing the elongation of the melanocyte dendrites of the present invention was effective in improving spots and freckles.
Calendula essence 2 of Example 2 1 part by weight 1,3-butanediol 5 parts by weight Glycerin 3 parts by weight Sodium citrate 0.1 part by weight Methylparaben 0.2 parts by weight Ethanol 8 parts by weight Water 82.7 parts by weight
<応用例3>
下記に示す処方に従って、皮膚外用医薬組成物を作成した。即ち、処方成分を攪拌分散して、皮膚外用剤を得た。このものは光による炎症を伴った、光による皮膚の黒化現象或いはソバカスに対して著効を示した。
実施例3のトウキンセンカのエッセンス3 0.5 重量部
プレドニゾロン 1 重量部
ワセリン 85 重量部
< Application 3 >
A pharmaceutical composition for external use on the skin was prepared according to the following formulation. That is, the prescription components were stirred and dispersed to obtain a skin external preparation. It showed a remarkable effect on light-induced skin blackening or freckles accompanied by light-induced inflammation.
Calendula essence 3 of Example 3 0.5 parts by weight Prednisolone 1 part by weight Vaseline 85 parts by weight
<応用例4>
以下に示す処方に従ってクリームを作製した。即ち、イ、ロ、ハをそれぞれ80℃に加熱溶解して、イにロを徐々に加え、更にハを加え乳化した後、ホモミキサーにより乳化粒子を均一化し、冷却してクリームを得た。このクリームは、炎症を伴うそばかす等の予防改善に優れた効果があった。
イ)
スクワラン 10 重量部
セタノール 3 重量部
ソルビタンセスキステアレート 2 重量部
ポリオキシエチレン(20)ベヘニルエーテル 2 重量部
ビタミンA酸 1 重量部
ロ)
1,3−ブタンジオール 5 重量部
実施例1のトウキンセンカのエッセンス1 1 重量部
カルボキシビニルポリマー 0.3 重量部
水 40 重量部
ハ)
水 37.3 重量部
水酸化カリウム 0.2 重量部
< Application Example 4 >
A cream was prepared according to the following recipe. That is, (a), (b), and (c) were each heated and dissolved at 80 ° C., (b) was gradually added to (a), and (c) was further added to emulsify the mixture. This cream was excellent in preventing and improving freckles with inflammation.
I)
Squalane 10 parts by weight Cetanol 3 parts by weight Sorbitan sesquistearate 2 parts by weight Polyoxyethylene (20) behenyl ether 2 parts by weight Vitamin A acid 1 part by weight b)
1,3-butanediol 5 parts by weight Essence of Calendula officinalis in Example 1 1 part by weight Carboxyvinyl polymer 0.3 part by weight Water 40 parts by weight c)
Water 37.3 parts by weight Potassium hydroxide 0.2 parts by weight
<応用例5>
下記に示す処方に従って、皮膚外用医薬組成物を作成した。即ち、処方成分を攪拌分散して、皮膚外用剤を得た。このものは光による炎症を伴った、光による皮膚の黒化現象或いはソバカスに対して著効を示した。
実施例2のトウキンセンカのエッセンス2 0.5 重量部
デキサメタゾン 1 重量部
ワセリン 85 重量部
< Application Example 5 >
A pharmaceutical composition for external use on the skin was prepared according to the following formulation. That is, the prescription components were stirred and dispersed to obtain a skin external preparation. It showed a remarkable effect on light-induced skin blackening or freckles accompanied by light-induced inflammation.
Calendula essence 2 of Example 2 0.5 parts by weight Dexamethasone 1 part by weight Vaseline 85 parts by weight
【0021】
【発明の効果】
本発明によれば、炎症を伴った色素異常やソバカスなどの色素異常に対して有効なメラノサイトのデンドライトの伸長抑制剤を提供することができる。
[0021]
【The invention's effect】
According to the present invention, it is possible to provide a melanocyte dendrite elongation inhibitor that is effective against pigment abnormality accompanied by inflammation and pigment abnormality such as freckles.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001275903A JP2003081807A (en) | 2001-09-12 | 2001-09-12 | Extension inhibitor of dendrite of melanocyte and cosmetic comprising the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001275903A JP2003081807A (en) | 2001-09-12 | 2001-09-12 | Extension inhibitor of dendrite of melanocyte and cosmetic comprising the same |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2003081807A JP2003081807A (en) | 2003-03-19 |
JP2003081807A5 true JP2003081807A5 (en) | 2008-10-16 |
Family
ID=19100687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001275903A Pending JP2003081807A (en) | 2001-09-12 | 2001-09-12 | Extension inhibitor of dendrite of melanocyte and cosmetic comprising the same |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2003081807A (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005055962A1 (en) | 2003-12-15 | 2005-06-23 | Kuraray Co., Ltd. | External preparations for skin |
CN106038399B (en) * | 2016-06-30 | 2018-11-13 | 山东师范大学 | A kind of foot film and preparation method thereof of the anti-chap deodorization of anti-inflammatory |
KR102318369B1 (en) * | 2019-11-15 | 2021-10-28 | 부산대학교 산학협력단 | Cosmetic composition for uv-screening comprising biocompatible nano-carrier |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60163810A (en) * | 1984-02-06 | 1985-08-26 | Dr Kawai Kurinitsuku:Kk | Toothpaste composition |
JPH11180854A (en) * | 1997-12-24 | 1999-07-06 | Lion Corp | Skin preparation for external use |
JP2000007546A (en) * | 1998-06-18 | 2000-01-11 | Yakult Honsha Co Ltd | Pigmentation inhibitor, skin cosmetic and skin external preparation using the same |
JP2000302634A (en) * | 1999-04-27 | 2000-10-31 | Ichimaru Pharcos Co Ltd | Cosmetic composition |
JP4395221B2 (en) * | 1999-08-18 | 2010-01-06 | 独立行政法人産業技術総合研究所 | Screening method for substances effective in the treatment of pigmented disorders |
JP4290841B2 (en) * | 2000-01-24 | 2009-07-08 | ポーラ化成工業株式会社 | Melanocyte dendrite elongation inhibitor and cosmetics containing the same |
JP2001199866A (en) * | 2000-01-24 | 2001-07-24 | Pola Chem Ind Inc | Dendritic growth-suppressing agent of melanocyte and cosmetic containing the same |
-
2001
- 2001-09-12 JP JP2001275903A patent/JP2003081807A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3499616B2 (en) | Application to hydroxytyrosol, melanin production inhibitor or lipid peroxide production inhibitor | |
JP3709363B2 (en) | Melanocyte dendrite elongation inhibitor and cosmetics containing the same | |
JP2003081746A (en) | Extension inhibitor of dendrite of melanocyte and cosmetic containing the same | |
JP2003081746A5 (en) | ||
JP4290841B2 (en) | Melanocyte dendrite elongation inhibitor and cosmetics containing the same | |
JP2002154919A (en) | Elongation inhibitor of dendrite of melanocyte and cosmetic comprising the same | |
JPH0672838A (en) | Cosmetic | |
JP2003081747A5 (en) | ||
JP2001199866A (en) | Dendritic growth-suppressing agent of melanocyte and cosmetic containing the same | |
JP2002154920A (en) | Elongation inhibitor of dendrite of melanocyte and cosmetic comprising the same | |
JP2003081807A5 (en) | ||
JP2009057312A (en) | Antioxidant and cosmetic containing the same | |
JP4646364B2 (en) | Melanocyte dendrite elongation inhibitor and cosmetics containing the same | |
JP2003081747A (en) | Extension inhibitor of dendrite of melanocyte and cosmetic containing the same | |
JP2003081807A (en) | Extension inhibitor of dendrite of melanocyte and cosmetic comprising the same | |
JP6281761B2 (en) | External preparation or internal preparation containing Hidakami Sebaya extract | |
KR20150132753A (en) | A preparation method of a leaf extract of Morus alba having antioxidant and antimicrobial activity | |
JP4441083B2 (en) | Melanocyte dendrite elongation inhibitor and cosmetics containing the same | |
JP3796190B2 (en) | Melanocyte dendrite elongation inhibitor and topical skin preparation containing the same | |
JP2003081748A (en) | Extension inhibitor of dendrite of melanocyte and cosmetic containing the same | |
JP6242575B2 (en) | Dendritic elongation inhibitor | |
JP5690149B2 (en) | External preparation or internal preparation | |
JP2001335502A (en) | Elongation inhibitor of dendrite of melanocyte and cosmetic comprising the same | |
JP2024155381A (en) | Whitening composition and topical skin preparation containing licorice extract extracted by a new extraction method | |
JP2004137166A (en) | Skin care preparation for external use, cell activator and antioxidant |